Log in

Relevant bibliographies by topics / Chemotherapy response / Journal articles

To see the other types of publications on this topic, follow the link: Chemotherapy response.

Journal articles on the topic 'Chemotherapy response'

Author: Grafiati

Published: 4 June 2021

Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chemotherapy response.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Koziel, M. J., and B. D. Walker. "Viruses, chemotherapy and immunity." Parasitology 105, S1 (1992): S85—S92. http://dx.doi.org/10.1017/s0031182000075399.

Full text

Abstract:

An increasing number of antiviral agents are presently in various stages of development and testing, and an increasing number have recently been licensed for use in humans. These drugs have been used extensively to treat viral infections in immunocompromised individuals, and these studies indicate that for many antiviral agents the response to therapy is highly dependent on the integrity of the underlying host immune response. In particular, the response to zidovudine, acyclovir and ganciclovir in persons with HIV-1 infection is highly dependent upon CD4 number, which can be considered a surro

APA, Harvard, Vancouver, ISO, and other styles

2

Seifter, E. J., P. A. Bunn, M. H. Cohen, et al. "A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate." Journal of Clinical Oncology 4, no. 9 (1986): 1365–73. http://dx.doi.org/10.1200/jco.1986.4.9.1365.

Full text

Abstract:

We administered combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin to 25 previously untreated patients with metastatic prostate cancer in order to assess the efficacy of chemotherapy before any hormonal manipulation. Hormonal therapy was administered only after progression of disease to chemotherapy. All 25 patients were followed until time of death and all were able to receive hormonal therapy. We did not find substantially improved response rates when combination chemotherapy was applied before endocrine treatment since the 33% objective response rate to chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Soyoung, and Clemens A. Schmitt. "Chemotherapy response and resistance." Current Opinion in Genetics & Development 13, no. 1 (2003): 90–96. http://dx.doi.org/10.1016/s0959-437x(02)00014-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hutchinson, Lisa. "MYC and chemotherapy response." Nature Reviews Clinical Oncology 7, no. 1 (2010): 4. http://dx.doi.org/10.1038/nrclinonc.2009.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Camitta, Bruce, Robert Wells, Annette Segura, K. Krishnan Unni, Kevin Murray, and David Dunn. "Osteoblastoma response to chemotherapy." Cancer 68, no. 5 (1991): 999–1003. http://dx.doi.org/10.1002/1097-0142(19910901)68:5<999::aid-cncr2820680515>3.0.co;2-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Vannier, Jean-Pierre, Françoise Flamant, Jacques Hemet, et al. "Pancreatoblastoma: Response to chemotherapy." Medical and Pediatric Oncology 19, no. 3 (1991): 187–91. http://dx.doi.org/10.1002/mpo.2950190308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Middleton, Justin, Daniel Stover, and Tsonwin Hai. "Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response." International Journal of Molecular Sciences 19, no. 11 (2018): 3333. http://dx.doi.org/10.3390/ijms19113333.

Full text

Abstract:

An emerging picture in cancer biology is that, paradoxically, chemotherapy can actively induce changes that favor cancer progression. These pro-cancer changes can be either inside (intrinsic) or outside (extrinsic) the cancer cells. In this review, we will discuss the extrinsic pro-cancer effect of chemotherapy; that is, the effect of chemotherapy on the non-cancer host cells to promote cancer progression. We will focus on metastasis, and will first discuss recent data from mouse models of breast cancer. Despite reducing the size of primary tumors, chemotherapy changes the tumor microenvironme

APA, Harvard, Vancouver, ISO, and other styles

8

Nugroho, Achmad, Johan Renaldo, and Wahjoe Djatisoesanto. "Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia." Folia Medica Indonesiana 56, no. 3 (2020): 178. http://dx.doi.org/10.20473/fmi.v56i3.22164.

Full text

Abstract:

The purpose of this study was to describe patients’ characteristics, correlation between staging non-seminoma cancer and chemotherapy response. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records in Soetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapy response, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N)

APA, Harvard, Vancouver, ISO, and other styles

9

Spaulding, M. B., S. G. Fischer, and G. T. Wolf. "Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group." Journal of Clinical Oncology 12, no. 8 (1994): 1592–99. http://dx.doi.org/10.1200/jco.1994.12.8.1592.

Full text

Abstract:

PURPOSE In 1984, the Department of Veterans Affairs Cooperative Studies Program began a trial in which patients with resectable squamous cell carcinoma of the larynx were randomized to receive standard surgery followed by radiation therapy or to receive neoadjuvant therapy with cisplatin and fluorouracil (5-FU) followed by radiation therapy for those achieving a greater than 50% tumor response to chemotherapy. This analysis reviews the tumor responses, toxicity, compliance, and long-term survival for those patients randomized to the chemotherapy arm. PATIENTS AND METHODS One hundred sixty-six

APA, Harvard, Vancouver, ISO, and other styles

10

Woods, Derek, and John J. Turchi. "Chemotherapy induced DNA damage response." Cancer Biology & Therapy 14, no. 5 (2013): 379–89. http://dx.doi.org/10.4161/cbt.23761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cahyanur, Rahmat, and Cosphiadi Irawan. "Cyclin D1 and Chemotherapy Response." Indonesian Journal of Cancer 15, no. 1 (2021): 41. http://dx.doi.org/10.33371/ijoc.v15i1.782.

Full text

Abstract:

Cyclin D1 is a protein that plays a role in the transition from the G1 to S phase of the cell cycle. Cyclin D1 expression has been found to increase in various malignancies and, in many studies, was associated with tumor growth, stage, lymph node involvement, distant metastases, and poor prognosis. Until now, studies on the association of cyclin D1 expression level with chemotherapy response have shown different results. An in-depth understanding of the cell cycle will allow doctors to develop target therapies that work when specific interventions are carried out at certain stages. Some studie

APA, Harvard, Vancouver, ISO, and other styles

12

Aigner, Kornelia, Stephan Drothler, Karl R. Aigner, and Karl R. Aigner. "Immune response during regional chemotherapy." Journal of Clinical Oncology 40, no. 16_suppl (2022): e14537-e14537. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14537.

Full text

Abstract:

e14537 Background: Regional chemotherapy is known to yield high drug concentrations in the treated tumor area while keeping systemic drug concentrations low. Regional Chemotherapy can be performed as an intra arterial infusion or isolated perfusion. Known perfusion techniques are isolated limb perfusion, hypoxic pelvic perfusion, hypoxic abdominal perfusion, upper abdominal perfusion, and isolated thoracic perfusion, Only little is known on the effect of chemotherapy on immune cells, especially not if chemotherapy is applied regionally. Since more and more immuno oncologic treatment possibilit

APA, Harvard, Vancouver, ISO, and other styles

13

Aigner, Kornelia, Stephan Drothler, Karl R. Aigner, and Karl R. Aigner. "Immune response during regional chemotherapy." Journal of Clinical Oncology 40, no. 16_suppl (2022): e14537-e14537. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14537.

Full text

Abstract:

e14537 Background: Regional chemotherapy is known to yield high drug concentrations in the treated tumor area while keeping systemic drug concentrations low. Regional Chemotherapy can be performed as an intra arterial infusion or isolated perfusion. Known perfusion techniques are isolated limb perfusion, hypoxic pelvic perfusion, hypoxic abdominal perfusion, upper abdominal perfusion, and isolated thoracic perfusion, Only little is known on the effect of chemotherapy on immune cells, especially not if chemotherapy is applied regionally. Since more and more immuno oncologic treatment possibilit

APA, Harvard, Vancouver, ISO, and other styles

14

Said, Ian, Steffen Böhm, Joanne Beasley, et al. "The Chemotherapy Response Score (CRS)." International Journal of Gynecological Pathology 36, no. 2 (2017): 172–79. http://dx.doi.org/10.1097/pgp.0000000000000307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Whittaker, S. J., and R. Russell Jones. "Histiocytosis X: Response to Chemotherapy." Journal of the Royal Society of Medicine 81, no. 6 (1988): 356–57. http://dx.doi.org/10.1177/014107688808100621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Judd, Julia, Chethan Ramamurthy, Elizabeth Handorf, et al. "Response and adverse events to chemotherapy after prior checkpoint inhibition in lung cancer." Journal of Clinical Oncology 36, no. 5_suppl (2018): 170. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.170.

Full text

Abstract:

170 Background: Historically, responses to chemotherapy beyond the first line for lung cancer range from 5-10%. The effect of antecedent immunotherapy on the response and reaction to chemotherapy is not well-established, but the immunomodulatory effects of many chemotherapy agents may lead to synergistic effects including both improved responses and unique toxicities. Methods: We reviewed the charts of patients at our institution who received at least one dose of an anti-PD-1 agent (aPD-1) as monotherapy prior to June 1, 2017. Patients with a diagnosis of non-small cell lung cancer or small ce

APA, Harvard, Vancouver, ISO, and other styles

17

Wong, Nathan Colin, Soleen Ghafoor, Hebert Alberto Vargas, Dean F. Bajorin, and Jonathan Coleman. "Radiographic predictors of pathologic response to neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-grade upper tract urothelial carcinoma." Journal of Clinical Oncology 38, no. 6_suppl (2020): 522. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.522.

Full text

Abstract:

522 Background: Neoadjuvant chemotherapy (NAC) has established survival benefits prior to radical cystectomy for bladder cancer, yet its role in upper tract urothelial carcinoma (UTUC) prior to nephroureterectomy (NU) is less clear. We performed a phase II clinical trial of NAC with gemcitabine and cisplatin (GC) in patients with UTUC to evaluate pathologic response. We investigated if radiographic responses could predict pathologic response. Methods: Patients with high-risk localized UTUC (high grade on biopsy and/or radiographic evidence of cT2-4 disease with positive select cytology) were r

APA, Harvard, Vancouver, ISO, and other styles

18

Hynninen, Johanna, Annika Auranen, Kirsti Dean, et al. "Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer." International Journal of Gynecologic Cancer 21, no. 9 (2011): 1573–78. http://dx.doi.org/10.1097/igc.0b013e3182225509.

Full text

Abstract:

ObjectiveHuman epididymis protein 4 (HE4) is a promising novel serum biomarker for the detection of early-stage epithelial ovarian cancer (EOC) and for the differential diagnosis between benign and malignant ovarian tumors. The objective of the present study was to determine the value of HE4 for monitoring the response to primary therapy in patients with advanced disease.MethodsSerum HE4 and cancer antigen (CA) 125 levels of 10 patients with advanced EOC and one patient with adenocarcinoma of unknown origin were measured preoperatively and during first-line chemotherapy. Seven patients were tr

APA, Harvard, Vancouver, ISO, and other styles

19

Deswangga, Muhammad Danar, and Yamin Alsoph. "CD8 + Tumoral as Predictor of Neoadjuvant Chemotherapy Response in Patients with Local Advanced Stage Breast Cancer." Sriwijaya Journal of Surgery 1, no. 2 (2018): 1–11. http://dx.doi.org/10.37275/sjs.v1i2.6.

Full text

Abstract:

ABSTRACT Introduction. Cancer until now has become a problem for health in the world including Indonesia. According to 2013 WHO data, cancer incidence has increased from 12.7 million cases in 2008 to 14.1 million cases in 2012. In local advanced breast cancer the treatment is neoadjuvant chemotherapy. Neoadjuvant therapy usually uses anthracycline or taxane based which can improve chemotherapy responses. Methods. This type of research is a CD8 + tumoral prognostic test used to predict neoadjuvant chemotherapy responses in patients with locally advanced breast cancer. The research w

APA, Harvard, Vancouver, ISO, and other styles

20

Rao, R., N. Saha, V. Mani, et al. "Pre-chemotherapy nutritional status and chemotherapy response: An observational study." Annals of Oncology 28 (September 2017): v543. http://dx.doi.org/10.1093/annonc/mdx388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Loredo, Felipe Pereira de, Sabrina Ramos Bianco, Sildomar Queiroz e. Silva, and Daniella Paula Dias Coelho. "Comparison between tomosynthesis and breast magnetic resonance imaging to assess tumor response after neoadjuvant chemotherapy: a case report." Núcleo do Conhecimento 12, no. 07 (2021): 56–65. https://doi.org/10.32749/nucleodoconhecimento.com.br/health/neoadjuvant-chemotherapy.

Full text

Abstract:

Increasingly, the surgical treatment of breast cancer has been preserving as much tissue as possible, avoiding mutilating surgeries such as mastectomies. Therefore, it is necessary to analyze the morphological characteristics, location and size of the tumor, and neoadjuvant chemotherapy is often used to reduce the tumor mass and thus enable conservative surgery. The evaluation of tumor response to neoadjuvant chemotherapy has magnetic resonance imaging as the gold standard, which, however, is not always accessible, has a high cost and is contraindicated for claustrophobic and obese patients. T

APA, Harvard, Vancouver, ISO, and other styles

22

Kasymjanova, G., N. MacDonald, M. Roseman, et al. "Anatomic response correlation with biological response." Journal of Clinical Oncology 27, no. 15_suppl (2009): 8092. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8092.

Full text

Abstract:

8092 Background: Chronic systemic inflammation is a well recognized strong adverse prognostic factor in advanced NSCLC. We have previously identified that in stage IIIB/IV NSCLC the presence of elevated C-reactive protein is associated with early progression of the disease and reduction in median survival. Little is known, however, about CRP behavior over time and its correlation with response to chemotherapy and survival. Methods: Newly diagnosed NSCLC with IIIB/IV disease had CRP measured prior to 1st treatment and after 2 cycles of chemotherapy between February 2005 and September 2008. For

APA, Harvard, Vancouver, ISO, and other styles

23

Aryanti, ,., Bethy Surjawathy Hernowo, and Hasrayati Agustina. "Clinicopathologic Characteristics and Chemotherapy Response of Classic Hodgkin Lymphoma: A Study in Tertiary Teaching Hospital." Journal of Drug Delivery and Therapeutics 10, no. 6-s (2020): 95–98. http://dx.doi.org/10.22270/jddt.v10i6-s.4638.

Full text

Abstract:

Background and Objective: Hodgkin Lymphoma (HL) is known as a malignancy of the lymphatic system and 90% of the HL is Classic Hodgkin Lymphoma (CHL). Prognostic factors that identify the patient's response to therapy are useful for optimizing the therapy. This study aims to assess the clinicopathological characteristics and chemotherapy response associated with CHL patients. Materials and Methods: This is a retrospective study of 40 patients diagnosed as CHL and treated with ABVD chemotherapy at Hasan Sadikin General Hospital/Padjadjaran University, Bandung, Indonesia during the period o

APA, Harvard, Vancouver, ISO, and other styles

24

Porcu, Pierluigi, Sumeet Bhatia, Matt Sharma, and Lawrence H. Einhorn. "Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors." Journal of Clinical Oncology 18, no. 6 (2000): 1181–86. http://dx.doi.org/10.1200/jco.2000.18.6.1181.

Full text

Abstract:

PURPOSE: To identify therapy-related or patient-related characteristics that predict response and long-term survival after failure of high-dose chemotherapy (HDCT) for germ cell tumors (GCT). PATIENTS AND METHODS: Between 1986 and 1997, 101 GCT patients relapsed after high-dose carboplatin and etoposide (VP-16) at Indiana University (Indianapolis, IN). Median time to relapse was 10 months (range, 1 to 17 months). HDCT was the first salvage treatment in 29 patients and second or later salvage treatment in 72 patients. RESULTS: Fifty-four of 101 patients received post-HDCT treatment. Of these, 4

APA, Harvard, Vancouver, ISO, and other styles

25

Grigg, Claud, Brian D. Reuland, Adrian G. Sacher, Randy Yeh, Naiyer A. Rizvi, and Catherine A. Shu. "Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9082. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9082.

Full text

Abstract:

9082 Background: Objective response rates (ORR) to chemotherapy beyond the first-line for advanced NSCLC are low (5-10%). Pre-clinical studies suggest that some chemotherapies may act, in part, through immune mediated mechanisms. Additionally, results from phase I/II studies of chemotherapy combined with immune checkpoint inhibitors (ICIs) suggest high response rates ( > 50%) and potential synergy. It is unknown whether chemotherapy is more efficacious when given after ICIs. Methods: We reviewed demographics, imaging, treatment history, and clinical course for all patients at our institutio

APA, Harvard, Vancouver, ISO, and other styles

26

Agarwal, Savita, Pinki Pandey, Megha Ralli, Vineet Chaturvedi, Kailash Mittal, and Shailendra Singh. "Assessment of pathological response to neoadjuvant chemotherapy in patients with breast carcinoma using Sataloff system." Archive of Oncology 25, no. 2 (2019): 13–18. http://dx.doi.org/10.2298/aoo190128001a.

Full text

Abstract:

Background: Neoadjuvant chemotherapy is frequently administered to patients with breast carcinoma. Response to chemotherapeutic regime can be assessed clinically as well as by pathological examination of the breast tissue. It is essential to accurately categorize the patients with residual disease according to the standard guidelines for pathological evaluation of breast specimens after neoadjuvant chemotherapy. The present study was undertaken to assess the histomorphological changes in mastectomy specimens and axillary lymphatic nodes of patients receiving neoadjuvant chemotherapy, grade the

APA, Harvard, Vancouver, ISO, and other styles

27

De Jong, Diederick De, Mohamed Otify, Inga Chen, et al. "Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction." Medicina 58, no. 11 (2022): 1611. http://dx.doi.org/10.3390/medicina58111611.

Full text

Abstract:

Background and Objectives: Approximately 10–15% of high-grade serous ovarian cancer (HGSOC) cases are related to BRCA germline mutations. Better survival rates and increased chemosensitivity are reported in patients with a BRCA 1/2 germline mutation. However, the FIGO stage and histopathological entity may have been confounding factors. This study aimed to compare chemotherapy response and survival between patients with and without a BRCA 1/2 germline mutation in advanced HGSOC receiving neoadjuvant chemotherapy (NACT). Materials and Methods: A cohort of BRCA-tested advanced HGSOC patients und

APA, Harvard, Vancouver, ISO, and other styles

28

Baumann, B. C., R. Ford, K. Dasse, and K. Zhou. "Inter-observer variability in chemotherapy trials for pancreatic cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 6522. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6522.

Full text

Abstract:

6522 Background: No studies have examined differences in imaging assessment of drug response for unresectable pancreatic cancer between investigators and independent central review panels. This study reports such discrepancies. Methods: 133 patients in two multi-center, randomized Phase II drug trials had their response assessed by measurement of tumor size or new lesions on serial CT scans. Protocols specified techniques for tumor measurement and defined responses as complete (CR) or partial responses (PR), stable (SD) or progressive disease (PD). Objective responses were confirmed by repeat

APA, Harvard, Vancouver, ISO, and other styles

29

Muñoz, Juan P., and Nicolás Lampe-Huenul. "Predictive Value of STC2 Gene Expression in Chemotherapy Response in Breast Cancer." Pharmaceuticals 18, no. 2 (2025): 235. https://doi.org/10.3390/ph18020235.

Full text

Abstract:

Background: Breast cancer is the most commonly diagnosed cancer among women, and resistance to chemotherapy presents a significant challenge in its treatment. Stanniocalcin-2 (STC2), a glycoprotein involved in calcium homeostasis and cellular stress responses, is frequently overexpressed in various human cancers. Despite its critical role in cellular adaptation to stress, the potential of STC2 as a biomarker for predicting chemotherapy response has not been evaluated. This study aimed to assess the potential of STC2 as a predictive biomarker of response to chemotherapy in breast cancer. Method

APA, Harvard, Vancouver, ISO, and other styles

30

Nugroho, Ahmad, Johan Renaldo, and Wahjoe Djatisoesanto. "Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia." Folia Medica Indonesiana 56, no. 3 (2021): 178. http://dx.doi.org/10.20473/fmi.v56i3.24536.

Full text

Abstract:

The purpose of this study to describe patientscharacteristics, correlation between stagingnon-seminomacancer and chemotherapyresponse. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records inSoetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapyresponse, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N) and metasta

APA, Harvard, Vancouver, ISO, and other styles

31

Gramatzki, Dorothee, Jörg Felsberg, Bettina Hentschel, et al. "Chemotherapy for adult patients with spinal cord gliomas." Neuro-Oncology Practice 8, no. 4 (2021): 475–84. http://dx.doi.org/10.1093/nop/npab017.

Full text

Abstract:

Abstract Background The incidence of spinal cord gliomas, particularly in adults is low, and the role of chemotherapy has remained unclear. Methods We performed a multicenter, retrospective study of 21 patients diagnosed with spinal cord glioma who received chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by magnetic resonance imaging. Data on radiotherapy were taken into consideration. Results Thirteen patients were diagnosed with astrocytic gliomas World Health Organization (WHO) grades 1-4, the remaining eight patients with ependymomas WHO grades 1

APA, Harvard, Vancouver, ISO, and other styles

32

Pisters, K. M., M. G. Kris, R. J. Gralla, M. B. Zaman, R. T. Heelan, and N. Martini. "Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials." Journal of Clinical Oncology 11, no. 9 (1993): 1757–62. http://dx.doi.org/10.1200/jco.1993.11.9.1757.

Full text

Abstract:

PURPOSE This report determines the incidence of pathologic complete response in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with mitomycin, vinca alkaloid, and high-dose cisplatin (MVP) chemotherapy, and estimates the effect of MVP on survival. PATIENTS AND METHODS We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). RESULTS All patients

APA, Harvard, Vancouver, ISO, and other styles

33

KUSUNOKI, YUKINA, TATSUNARI FUKUOKA, ATSUSHI SUGIMOTO, et al. "Impact of Changes in Psoas Muscle Index on Prognosis in Patients With Colorectal Liver Metastases." Cancer Diagnosis & Prognosis 5, no. 1 (2025): 72–82. https://doi.org/10.21873/cdp.10414.

Full text

Abstract:

Background/Aim: Reduction in skeletal muscle mass during chemotherapy is associated with poor outcomes. This study investigated the impact of changes in the psoas muscle index (PMI) on the prognosis of patients with unresectable colorectal liver metastases (CRLM) undergoing chemotherapy, including subgroup analyses based on the initial treatment response assessment. Patients and Methods: We evaluated 47 patients with unresectable CRLM who underwent systematic chemotherapy and assessed changes in PMI to determine their prognosis. Results: Changes in PMI were significantly associated with the pr

APA, Harvard, Vancouver, ISO, and other styles

34

Temam, Stéphane, Antoine Flahault, Sophie Périé, et al. "p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck." Journal of Clinical Oncology 18, no. 2 (2000): 385. http://dx.doi.org/10.1200/jco.2000.18.2.385.

Full text

Abstract:

PURPOSE: To determine whether p53 gene status predicts tumor responses to platinum- and fluorouracil-based induction chemotherapy in locoregionally advanced squamous cell carcinomas of the head and neck. PATIENTS AND METHODS: Tumor responses of 105 patients were measured at the primary tumor site. Objective response and major response were defined by a 50% and 80% reduction in tumor size, respectively. All coding parts of p53 gene were directly sequenced. p53 expression in tumor cells was determined by immunohistochemistry. Human papillomavirus infection was detected by polymerase chain reacti

APA, Harvard, Vancouver, ISO, and other styles

35

Yun, Won-Gun, Youngmin Han, Mirang Lee, et al. "1170 PROGNOSTIC SIGNIFICANCE OF RESPONSE TO NEOADJUVANT FOLFIRINOX CHEMOTHERAPY AND EFFICACY OF ADJUVANT CHEMOTHERAPY ACCORDING TO RESPONSE TO NEOADJUVANT FOLFRINOX CHEMOTHERAPY." Gastroenterology 164, no. 6 (2023): S—1509. http://dx.doi.org/10.1016/s0016-5085(23)04559-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Cao, Yanshuo, Qing Chang, Michael Cabanero, et al. "Tumor platinum concentrations and pathological responses following preoperative cisplatin-containing chemotherapy in gastric or gastroesophageal junction cancer patients." Journal of Clinical Oncology 36, no. 4_suppl (2018): 76. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.76.

Full text

Abstract:

76 Background: Perioperative chemotherapy plus surgical resection is a standard of care for locally advanced gastric or gastroesophageal junction (GEJ) cancers. There is a wide range in tumor response following cisplatin-containing preoperative chemotherapy. We investigated the relationship between tumor platinum levels and pathological tumor responses in gastric or GEJ cancer patients following preoperative chemotherapy. Methods: Tumor and adjacent normal tissues were retrieved. Pathological responses were assessed per standard criteria. Tissue platinum concentrations were determined with hig

APA, Harvard, Vancouver, ISO, and other styles

37

Dwary, Ashish D., Samip Master, Abhishek Patel, et al. "Excellent response to chemotherapy post immunotherapy." Oncotarget 8, no. 53 (2017): 91795–802. http://dx.doi.org/10.18632/oncotarget.20030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Liu, Mou-Ze, Howard L. McLeod, Fa-Zhong He, et al. "Epigenetic perspectives on cancer chemotherapy response." Pharmacogenomics 15, no. 5 (2014): 699–715. http://dx.doi.org/10.2217/pgs.14.41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Beeharry, N., and D. Broccoli. "Telomere Dynamics in Response to Chemotherapy." Current Molecular Medicine 5, no. 2 (2005): 187–96. http://dx.doi.org/10.2174/1566524053586554.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Laino, Charlene. "Gene Assay Predicts Response to Chemotherapy." Oncology Times 27, no. 3 (2005): 23–24. http://dx.doi.org/10.1097/01.cot.0000288815.31448.ad.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

QUILTY, PHYLLIS M. "Urachal Carcinoma: a Response to Chemotherapy." British Journal of Urology 60, no. 4 (1987): 372. http://dx.doi.org/10.1111/j.1464-410x.1987.tb04992.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Miyamoto, Yosuke, Nobukazu Fujimoto, Naofumi Hara, et al. "Lymphohistiocytoid Mesothelioma With Response to Chemotherapy." Chest 146, no. 4 (2014): 483A. http://dx.doi.org/10.1378/chest.1993777.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

KUMAR, R. "Atypical response to chemotherapy in neurotuberculosis." British Journal of Neurosurgery 12, no. 4 (1998): 344–48. http://dx.doi.org/10.1080/02688699844862.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Grant, R., B. C. Liang, M. A. Page, D. L. Crane, H. S. Greenberg, and L. Junck. "Age influences chemotherapy response in astrocytomas." Neurology 45, no. 5 (1995): 929–33. http://dx.doi.org/10.1212/wnl.45.5.929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Dittler, H. J., U. Fink, and G. R. Siewert. "Response to Chemotherapy in Esophageal Cancer." Endoscopy 26, no. 09 (1994): 769–71. http://dx.doi.org/10.1055/s-2007-1009101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Cammermeyer, Margarethe. "Tumor Response to Two Chemotherapy Regimens." Journal of Neuroscience Nursing 18, no. 2 (1986): 101. http://dx.doi.org/10.1097/01376517-198604000-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Pazdur, R. "Response Rates, Survival, and Chemotherapy Trials." Journal of the National Cancer Institute 92, no. 19 (2000): 1552–53. http://dx.doi.org/10.1093/jnci/92.19.1552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Epperla, Narendranath, and David E. Weissman. "Chemotherapy: Response and Survival Data #99." Journal of Palliative Medicine 19, no. 9 (2016): 1011. http://dx.doi.org/10.1089/jpm.2016.0221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Grant, R., B. C. Liang, J. Slattery, H. S. Greenberg, and L. Junck. "Chemotherapy response criteria in malignant glioma." Neurology 48, no. 5 (1997): 1336–40. http://dx.doi.org/10.1212/wnl.48.5.1336.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kumar, Raj, Mahesh Prakash, and Sanjeev Jha. "Paradoxical Response to Chemotherapy in Neurotuberculosis." Pediatric Neurosurgery 42, no. 4 (2006): 214–22. http://dx.doi.org/10.1159/000092357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!